Mutations in the lipid transporter ABCA7 are known to elevate the risk of Alzheimer’s disease, but how they do so has been murky. Now, scientists led by Li-Huei Tsai at MIT in Cambridge, Massachusetts ...
Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...
Some evidence suggests that regular consumption of fish, nuts, fruits, veggies, and whole grains, aka the Mediterranean diet, reduces a person’s risk of dementia. APOE4, on the other hand, increases ...
Short or tall? Curly hair or straight? DNA holds those answers, but it can also reveal much more. In the September 8 issue of Nature Genetics, scientists led by Aliza and Thomas Wingo at the ...
The infamous paired helical filaments (PHFs) of tau that sprawl across the brain in Alzheimer’s disease are the end products of a multiyear process. What drives tau to form these specific filaments in ...
This active vaccine was designed to overcome the weak immune system of aged populations while avoiding auto-immune T cell responses. The Lu AF20513 epitope intersperses three repeats of the first 12 ...
Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...
On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...
Results of the eagerly awaited Phase 3 clinical trial of LMTM, a derivative of the dye methylene blue, generated consternation at the Alzheimer’s Association International Conference 2016, held July ...
As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback